LifeX 2050 Longevity Income ETFLFAI

The LFAI ETF, marketed as a gateway to the future of longevity, has recently seen increased attention, but its underlying holdings tell a different story. The fund, which tracks the LifeX 2050 Longevity Index, is dominated by biotech and healthcare stocks like CRISPR Therapeutics and Vertex Pharmaceuticals, rather than the futuristic longevity labs its name might suggest.

For investors, the real question isn’t whether humans will live longer by 2050, but whether the LFAI’s 0.75% expense ratio will eat into returns faster than any life-extending technology can save them. The fund’s $50 million in AUM reflects some market interest, but it’s not the kind of scale that usually accompanies such a high-concept theme.

While the SEC EDGAR filings reveal the fund’s traditional biotech holdings, they also highlight the gap between its marketing and its reality. The LFAI replicates its index rather than investing directly, adding another layer of abstraction-and cost-to the mix. Meanwhile, the FINRA Fund Analyzer shows that the fund’s liquidity, while sufficient, isn’t exactly groundbreaking for an ETF.

The chart route via Nasdaq suggests steady but unremarkable performance, with the fund’s tracking method ensuring it stays close to its index. However, the lack of parsed financial numbers means investors are left to wonder whether the fund’s longevity promises extend to their wallets.